Previous 10 | Next 10 |
Esperion Therapeutics (ESPR): Q1 GAAP EPS of -$3.50 misses by $0.77.Revenue of $8M (+344.4% Y/Y) misses by $11.93M.FY 2021 guidance: Research and development expenses for the are expected to be $120 million to $130 million; selling, general and administrative expenses are expected to be $200 ...
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tab...
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy – – Nearly half of trial participants are women, a significantly higher proportion than have been included in any ot...
Esperion Therapeutics (ESPR) has signed a new licensing agreement granting the exclusive rights to Daiichi Sankyo Company (DSKYF) to commercialize bempedoic acid and the bempedoic acid/ezetimibe combination tablet in additional countries.The deal allows Daiichi Sankyo to commercialize th...
ANN ARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced that an investor group led by Oberland Capital Management LLC (Oberland Capital) agreed to provide the third and final tranche of funding under the revenue-based funding agreement total...
– Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments – – Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1 Billion – – Demonstrates Daiichi Sankyo Group...
ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesday, May 4, 2021. Following the release, company management will host a webcast and co...
ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 202...
Esperion (ESPR) announces results of a Phase 2 study evaluating the combination of NEXLETOL (bempedoic acid) 180 mg Tablet, ezetimibe 10 mg and atorvastatin 20 mg in patients with hypercholesterolemia showed reduction in low-density lipoprotein cholesterol ((LDL-C)) levels by 60.5% vs. p...
- Results of bempedoic acid, ezetimibe and atorvastatin triple therapy study published in March issue of Atherosclerosis - - Combining three orally administered once-daily LDL-C lowering medicines has not been previously studied, though combination therapy is common in other are...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...